Advertisement

Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany

  • Olaf OrtmannEmail author
  • Julie Torode
  • Chris Harrison
  • Johannes Bruns
  • Ulrike Helbig
  • For the Participants of the ERTM
Review – Clinical Oncology
  • 16 Downloads

Abstract

Purpose

To identify key factors for successful integration of translational science into cancer care.

Results

Organisation of the health care system matters to optimally bridge between public and private cancer research, cancer registries and routine care. Currently, there are deficits on various levels of connectivity. These hamper rapid and optimal transfer of innovation.

Conclusion

To overcome the deficits, strategies of data sharing and infrastructures allowing fast-track implementation of translational research findings into routine care need to be developed.

Keywords

Basic cancer research Translational cancer research Clinical cancer research Cancer care 

Notes

Acknowledgements

List of all participants: Europe/Association of European Cancer Leagues: Nicolas Philippou, Board member of the Association of European Cancer Leagues, Chief Executive, The Cyprus Association of Cancer Patients and Friends, Nicosia, Cyprus. European Commission: Dr. Stefan Schreck, Chef d’unité, Programme santé et maladies chroniques, Direction générale de la santé et sécurité alimentaire, Luxembourg. Slovenia: Prof. Dr. Tit Albreht, Head of the Centre for Health Care—National Institute of Public Health, Lubljana. Spain: Prof. Dr. Josep Borras, Scientific Coordinator Spanish Cancer, Director, Catalonian Cancer Strategy, Hospital Duran I Reynals, Barcelona. Global/Union of International Cancer Control: Dr. Julie Torode, Deputy CEO, Advocacy and Networks Director, Union for International Cancer Control (UICC), Geneva. The Netherlands: Prof. Dr. Jan-Willem Coebergh, former Head of the section Cancer Surveillance of the Department of Public Health, Erasmus MC Rotterdam and of Research at the Comprehensive Cancer Centre South (IKZ) Eindhoven. United Kingdom: Prof. Chris Harrison, National Clinical Director for Cancer, NHS England, Medical Director (Strategy), The Christie NHS Foundation Trust, Manchester. Germany: Dr. Johannes Bruns, Secretary-General of the German Cancer Society, Berlin, Dr. Ulrike Helbig MBA, General Manager Section A, German Cancer Society, Berlin, Prof. Dr. Andreas Hochhaus, Board Member of the German Cancer Society, Director Dept. Haematology and Clinical Oncology, Director of the University Tumor Centre Jena, PD Dr. Monika Klinkhammer-Schalke, Director Tumor Centre Regensburg, Managing Board Member German Tumor Centres Work Group, Berlin, Dr. Christoph Kowalski, Research Coordination Certification, German Cancer Society, Berlin, Prof. Dr. Margarete Landenberger, Institute of Health and Nursing Science, Medical Faculty of Martin-Luther University Halle-Wittenberg, Halle (Saale), Dr. Katrin Mugele, Press officer, German Cancer Society, Berlin, Prof. Dr. Olaf Ortmann, President of the German Cancer Society, Director Department Gynaecology and Obstetrics, University Medical Center, Caritas-Hospital St. Josef, Regensburg, Ralf Rambach, Director of the Board, Haus der Krebsselbsthilfe Bundesverband e. V., Bonn.

Author contributions

OO: manuscript writing, editing. JT: manuscript writing, editing. CH: manuscript writing, editing. JB: manuscript writing, editing. UH: manuscript writing, editing.

Funding

No funding was received.

Compliance with ethical standards

Conflict of interest

Author O. Ortmann M.D. declares that he has no conflict of interest. Author J. Torode declares that she has no conflict of interest. Author C. Harrison declares that he has no conflict of interest. Author J. Bruns declares that he has no conflict of interest. Author U. Helbig M.D. declares that she has no conflict of interest.

Human and animal rights statement

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. Ortmann O, Helbig U, Torode J (2016a) Improving cancer care in Europe: which institutional health structures might be beneficial and why? 1. European Roundtable Meeting (ERTM), 16th May 2014, Berlin, Germany. J Cancer Res Clin Oncol. 142(1):1–4.  https://doi.org/10.1007/s00432-014-1906-x (Epub 2015 Feb 3) CrossRefGoogle Scholar
  2. Ortmann O, Torode J, Helbig U (2016b) Improving structural development in oncology: transformation of theoretical health care standards and knowledge into a practical approach—2nd European Roundtable Meeting (ERTM), May 8, 2015, Berlin. Germany. J Cancer Res Clin Oncol 142(4):807–811.  https://doi.org/10.1007/s00432-015-2052-9 (Epub 2015 Oct 19) CrossRefGoogle Scholar
  3. Ortmann O, Helbig U, Rösler W (2017) Current developments in cancer care: including the patients’ perspective—3rd European Roundtable Meeting (ERTM) June 17, 2016, Berlin, Germany. J Cancer Res Clin Oncol 143(4):673–676.  https://doi.org/10.1007/s00432-016-2320-3 (Epub 2016 Dec 17) CrossRefGoogle Scholar
  4. Ortmann O, Helbig U, Torode J, Schreck S, Karjalainen S, Bettio M, Ringborg U, Klinkhammer-Schalke M, Bray F (2018) Quality control and improvement of cancer care—what is needed? 4th European Roundtable Meeting (ERTM) May 5th, 2017, Berlin. Germany. J Cancer Res Clin Oncol 144:1097–1102CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.German Cancer SocietyBerlinGermany
  2. 2.Union for International Cancer Control (UICC)GenevaSwitzerland
  3. 3.Department of Gynecology and ObstetricsUniversity Medical Center RegensburgRegensburgGermany
  4. 4.The Christie NHS Foundation TrustManchesterUK

Personalised recommendations